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BACKGROUND. Men with biochemical recurrence of prostate cancer following local
therapies often use natural supplements in an attempt to delay metastases and/or avoid the
need for more aggressive treatments with undesirable side-effects. While there is a growing
body of research into phytotherapeutic agents in this cohort, with some promising results, as
yet no definitive recommendations can be made. This pilot study was undertaken to assess
the feasibility of a fully-powered study to examine the effects of this phytotherapeutic
intervention (containing turmeric, resveratrol, green tea and broccoli sprouts) on PSA
doubling time in men with biochemical recurrence with a moderate PSA rise rate.
METHODS. A double blind, randomized, placebo-controlled parallel trial was conducted
with 22 men with biochemically recurrent prostate cancer and a moderate rise rate (PSA
doubling time of 4–15 months and no evidence of metastases from conventional imaging
methods). Patients were randomized to either the active treatment arm or placebo for
12 weeks. The primary endpoints were feasibility of study recruitment and procedures, and
measurement of proposed secondary endpoints (prostate symptoms, quality of life, anxiety,
and depression as measured on the EORTC QLQ-C30 and PR-25, the IPSS and HADS). Data
were collected to estimate PSA-log slopes and PSA-doubling times, using a mixed model, for
both the pre-intervention and post-intervention periods.
RESULTS. Adherence to study protocol was excellent, and the phytotherapeutic interven-
tion was well-tolerated, with similar numbers of mild-to-moderate adverse events in the
active and placebo arms. Both the intervention and data collection methods were acceptable
to participants. No statistical difference between groups on clinical outcomes was expected in
this pilot study. There was between-subject variation in the PSA post treatment, but on
average the active treatment group experienced a non-significant increase in the log-slope of
PSA (pre-treatment doubling time¼ 10.2 months, post-treatment doubling time¼ 5.5
months), and the placebo group experienced no change in the log-slope of PSA
(pre-treatment doubling time¼ 10.8 months, post-treatment doubling time¼ 10.9 months).
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CONCLUSION. The findings suggest that a fully powered study of this combination is
feasible in men with biochemically recurrent prostate cancer and a moderate PSA rise rate.
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INTRODUCTION
Approximately 30–40% of men treated for local-
ised prostate cancer (PC) with definitive local
therapies such as radical prostatectomy or radia-
tion therapy will develop biochemical recurrence
(BCR) of disease, detected by a rising serum
prostate-specific antigen (PSA) [1,2]. BCR signifies
the presence of incurable disease in most cases,
however, there will typically be a period of several
years of observation before further therapy is
justified due to the indolent nature of many BCR
cases [3]. Salvage therapy for BCR is mostly based
around androgen deprivation therapy (ADT) [4,5]
that is associated with significant toxicities such as
hot flushes, loss of libido, sarcopenia, metabolic
syndrome, and bone loss [6–8]. Understandably,
many men with BCR attempt to delay the initia-
tion of salvage therapies with the use of natural
supplements [6,9].
Epidemiological and dietary studies support the
PC chemopreventative effects of diets rich in
plant-derived polyphenols, such as curcumin in
turmeric; resveratrol found in grape skins and red
wine, catechins in green tea; and glucosinolates
(notably the isothiocyanate sulforaphane in broc-
coli sprouts) [10–15]. Data from in vitro, in vivo,
and clinical trials also lend support to their
anticancer activities [16–27]. Randomized con-
trolled trials (RCTs) of catechins from the leaves
of green tea (Camellia sinensis, Theaceae family),
notably epigallocatechin-3-gallate (EGCG), support
its chemopreventive activity [28,29], and benefits
on PSA dynamics in men with prostate
cancer [30–32]. In a RCT with 78 men with BCR,
sulforaphane (an enzymatic degradation product
from glucoraphanin in broccoli sprouts), 60mg
daily (NutrinovTM) for 6 months resulted in a 78%
(21.7 month) increase in PSA-doubling time (PSA-
DT) compared to placebo (12.2 months), with no
effect on testosterone, and good tolerability [33].
In a recent RCT of 203 men with BCR, the
combination of green tea leaf, turmeric root,
broccoli, pomegranate seed, and whole fruit
(Pomi-T1) for 6 months showed a significant
suppression of PSA progression [34,35].
While these phytotherapeutic agents are readily
available, further human clinical trial data
are required to fully support the use of these inter-
ventions, and particularly for the commonly-used
multi-component formulations.
In the present study, we hypothesized that a
combination therapy containing turmeric (Curcuma
longa, L., Zingiberaceae family), resveratrol from Japa-
nese knotweed (Polygonum cuspidatum Sieb. and Zucc
[Polygonaceae family]), green tea (Camellia sinensis,
Theaceae family), and broccoli sprouts (Brassica oler-
acea L. var. italic, Cruciferae/Brassicaceae family)
would be well tolerated and safe to administer to a
cohort of men with BCR and a moderate rate of PSA
rise. We designed the study to evaluate both these
hypotheses, along with the feasibility of a placebo-
controlled double-blinded design.
MATERIALS AND METHODS
Study Participants
Participants were recruited from Peter MacCal-
lum Cancer Centre in East Melbourne, Australia,
into this placebo-controlled double-blinded parallel
randomized controlled trial. Men were allocated 1:1
between the control (placebo) and experimental
arms. The trial was approved by the Human
Research Ethics Committee of the Peter MacCallum
Cancer Centre and the University of Melbourne
Human Ethics Sub-Committee, and the trial regis-
tered on the Australian New Zealand Clinical Trials
Registry (ANZCTR number: 366895). All partici-
pants were required to provide informed consent
prior to enrolment.
To be eligible, men were required to be aged 18
years and over, and to have developed BCR following
treatment for histologically confirmed prostate adeno-
carcinoma with localized therapy. At enrolment, men
required a minimum PSA value at of either
(i) 0.4 ng/mL if the primary treatment was radical
prostatectomy; or (ii) PSA nadirþ 2 ng/ml if the
primary treatment was radical radiotherapy, and a
moderate PSA rise (PSA-DT) of 4–15 months, as
demonstrated by three or more PSA measurements
obtained at least 3 months apart over a minimum of
12 months prior [6]. Testosterone at baseline was
required to be at least 6.9 nmol/L along with adequate
hepatic function denoted by GGT less than double the
upper limit normal (ULN), bilirubin less than
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1.5ULN, and adequate renal function (eGFR by
Cockcroft-Gault or comparable calculation
>50ml/min) and creatinine 70–120mmol/L.
Men were excluded if there was evidence of
metastastic disease on conventional imaging methods
(computed tomography and nuclear bone scan).
Other exclusion criteria included any of the following:
significant uncontrolled comorbid condition, receiv-
ing concurrent chemotherapy or having previously
previously received cytotoxic chemotherapy or andro-
gen ablative therapy for recurrent disease; currently
receiving biological response modifiers or high dose
prednisolone (50mg/day); history of intolerance to
caffeine or any of the trial interventions.
Study Intervention
The intervention consisted of two tablets twice
daily of:
 turmeric (Curcuma longa) rhizome extract
[TUMEP25] 25:1, standardised for curcumin 95%,
assay 95–105% total curcuminoids; curcumin
100mg (400mg/day);
 resveratrol from Polygonum cuspidatum extract dry
concentrate [POLEP100], standardised, 100:1, con-
taining not less than 50% resveratrol, 30mg
(120mg/day);
 green tea (Camellia sinensis) leaf dry concentrate
[GRTEPE 50%], standardised, 25:1, containing not
less than 50% polyphenols; catechins 100mg
(400mg/day; [Details of the analytic methods for
standardization are available on request.]; and two
capsules twice daily of
 broccoli (Brassica oleracea var. italica) sprout concen-
trate [BROEPE] 20:1, equivalent to fresh sprouts
2,000mg (8 g/day).
Matching placebo tablets contained the exci-
pients: microcrystalline cellulose, calcium hydrogen
phosphate, magnesium stearate, hypromellose. Ac-
tive and placebo tablets were color-coated with iron
oxide to give an identical appearance in terms of
size, color, coating, and weight. The placebo capsu-
les contained powdered green oats, aerial parts
(Avena sativa, L., Graminaceae family), 100mg to
color-match the active intervention. Avena sativa has
no demonstrated activity in prostate cancer [36,37].
Tablets and broccoli sprout powder for capsules
were manufactured according to the Code of Good
Manufacturing Practice; the powdered green oats
herb (the placebo for the broccoli sprout powder) was
manufactured as a food. All were supplied by
MediHerb/Integria Healthcare Australia Pty Ltd,
who provided quality assurance data. Batch numbers
for the active and placebo tablets were 160749 and
160750, respectively.
Retention samples of raw materials and finished
tablets are securely stored at MediHerb; these were
validated by chemical fingerprinting against verified
botanical samples maintained at the Southern Cross
University Herbarium. These underwent full internal
identity and microbiological (BP) testing. Thin layer
chromatography was used for identification and
qualitative testing; quantitative analysis to determine
total curcuminoids, resveratrol, and total catechins
was by high performance liquid chromatography.
Details of the method for performing this analysis are
available on request. Powders were encapsulated
by Dartnell’s compounding chemist, Surrey Hills,
Melbourne, Australia. The batch number for the
broccoli capsules was RD237, and for the green oat
(placebo) capsules, 014E133. All products are included
on the Australian Register of Therapeutic goods as
Listed Medicines, (after Medicines) and were admin-
istered within standard dosage levels.
The active and placebo supplements were supplied
directly to Peter MacCallum Cancer Centre pharmacy
from MediHerb/Integria and Dartnell’s pharmacy,
and were dispensed to trial participants in sealed
containers. At the end of the study, any remaining
tablets were returned to the study centre, and manu-
ally counted.
Outcome Measures
PSA measurements (three to six for each patient)
were obtained from hospital records for at least
12 months prior to enrolment to estimate PSA-DT.
Baseline PSA was measured at usual care visits
which ranged from 9 days to 1.8 months prior to
randomization. However, one baseline PSA was
not performed in a timely fashion due to an
administrative error. The post-randomization PSA
measurement was obtained within a week of end-
of-treatment in most cases. Clinical process mea-
sures collected at baseline were PSA, blood
pressure, urea and electrolytes, liver function tests
and oestradiol (E2). Body mass index was calcu-
lated, and Karnofsky performance scale was rated
at baseline. Health-related quality of life measures
were the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire-
C30 (EORTC QLQ-C30) version 3, and Prostate 25
administered at baseline and week 12, and the
International Prostate Symptom Score (IPSS) and
Hospital Anxiety and Depression Scale (HADS).
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Dietary intake of trial substances were recorded
in men’s weekly diaries, along with adverse
events, and collected at monthly telephone follow-
ups. Adverse events were recorded on the
Case Report Form, and graded according to the
National Cancer Institute (NCI) common toxicity
scale.
Sample Size
This pilot study was not powered to detect a
statistical difference between groups on clinical out-
comes. A pragmatic sample size of up to 40 men was
chosen to test recruitment procedures and acceptabil-
ity of all aspects of running the study, including
TABLE I. Baseline Characteristics of Participants (n¼ 20)
Placebo n¼ 11 Active n¼ 9
Age at trial start (years)
Mean (SD) 75 (8.3) 69 (6.4)a
Median (range) 77 (58–84) 69 (56–77)
Weight in kg 83 (11.7) 78 (120)
Height in cm 175 (7.0) 171 (66)
BMI 27 (2.7) 26 (3.5)
Ethnicity, n (%)
Caucasian 11 (100%) 7 (78%)
Asian 0 (0%) 2 (22%)
Education, n (%)
Year 11 or under 7 (64%) 1 (11%)
Year 12 2 (18%) 3 (33%)
TAFE or university 1 (9%) 5 (56%)b
Postgraduate 1 (9%) 0 (0%)
Smokers, n (cigarettes per day, n) 0 1 (<10)
Standard alcoholic drinks per week 2.5 (1.2) 2.1 (1.1)
Dietary caffeine: cups of tea/coffee/cola drinks/day 4.8 (5.4) 3.7 (1.5)
Dietary intake of trial foods
Green tea/cups per day 0.3 (0.7) 0.2 (0.4)
Turmeric/curries per week 0.1 (0.3) 0.3 (0.7)
Broccoli, serves per week 1.6 (2.1) 2.0 (2.5)
Red wine, standard glasses per week 4.8 (8.0) 2.7 (3.5)
Prior herbal medicine use, n (found it effective, n) 1 (1) 1 (1)
Prior use of trial supplements, n (found it effective, n) (0) (0)
Karnofsky, n (%)
100 8 (73%) 9 (100%)
90 2 (18%) 0 (0%)
PSA values at screening (ng/ml)
Mean (SD) 8.39 (6.03) 5.95 (8.74)
Median (range) 7.5 (2.4–22) 4.2 (0.43–28)
PSA-DT at screening (months)c 10.8 10.2
Pre-operative Gleason score, n (%)
6 1 (9%) 2 (22%)
7 6 (55%) 4 (45%)
8 1 (9%) 2 (22%)
9 3 (27%) 1 (11%)
Prior treatment, n (%)
Surgery only 1 (9%) 2 (22%)
Radiotherapy only 9 (82%)b 2 (22%)
Both surgery and radiotherapy 1 (9%) 5 (56%)b
Months since first treatment, mean (SD) 107.4 (61.6) 94.2 (45.3)
Mean (SD) unless otherwise stated.
aSignificant difference P<.05.
bSignificant difference P<.05 using chi-square x2.
cCalculated using linear mixed model.
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measuring proposed study endpoints at baseline and
throughout the observation period.
Randomization
Eligible patients were allocated to active treatment
or placebo by the unblinded pharmacist according to
the next available sequence in a randomization sched-
ule, produced by a clinical trials statistician using a
reproducible permuted block method. To evaluate the
success of blinding, participants’ assessments of their
group assignations were elicited at the end of the
treatment phase prior to code breaking, and subse-
quently compared with actual group allocation.
Statistical Methods
Data were analyzed for all eligible randomized
participants. Compliance was considered as
greater than 70% of tablets taken. Results are
expressed as means SD; alpha level was set at
0.05.
A linear mixed model was used to assess the
impact of the intervention on the doubling time of
PSA. Log(PSAþ 0.1) was the response variable.
The fixed effects were an intercept, an effect for
intervention group, and four slopes corresponding
to pre- and post-randomization time for both
treatment groups. The model included a partici-
pant-specific intercept, participant-specific pre- and
post-randomization slopes plus measurement error.
The addition of 0.1 to PSA is to avoid taking the
logarithm of zero and to better agree with the
assumptions of the model. The addition of 0.1 is
ignored in the calculation of the doubling time. The
estimated slope for each time period and group can
be converted into a doubling time using the
equation:
doublingtime ¼ natural logarithmð2Þ=slope:
Also presented are 95% confidence intervals for the
doubling time. The effect of the treatment is evaluated
by: (i) comparing the post randomization slopes
between the two groups; (ii) by comparing the change
in slope at randomization between the two groups;
and (iii) by comparing the pre and post randomiza-
tion log PSA slopes separately for each treatment
group.
Independent samples t-tests were used to compare
groups at baseline on continuous variables. A
Pearson’s chi-square exact test was used to compare
differences in categorical variables. For secondary
endpoints of EORTC QLQ-C30 and Prostate 25, the
HADS and the IPSS, data are presented descriptively
as means and standard deviations. Statistical analysis
was conducted at the University of Melbourne and
University of Michigan using R, STATA-IC12, and
SAS 9.4.
Safety Monitoring
Two general practitioners with experience of phy-
totherapy were recruited as safety monitors, and were
available for rapid consultation in the event of
suspected serious adverse events.
RESULTS
Twenty-two of 31 eligible patients were random-
ized between December 2014 and June 2015. All
TABLE II. Treatment-Related Adverse Events
Adverse event Gradea Number of men Group Week reported Likelihood related
Nocturia 1 2 Active 1–2 Probably
Heartburn 2 1 Active 8–12 Probably
Headache 1 1 Active 4 Possibly
Restlessness 1 1 Active 9–12 Probably
aGrade 1¼mild; grade 2¼moderate.
TABLE III. PSA Doubling Times by Group and Period of Assessment
Pre-baseline
PSA-DTa
Baseline to 12 weeks
PSA-DTa
Placebo group (n¼ 11) 10.8 months, 95%CI¼ (8.5,14.4) 10.9 months, 95%CI¼ (5.2, infinity)
Active group (n¼ 9) 10.2 months, 95%CI¼ (8.1,13.9) 5.5 months, 95%CI¼ (3.4,13.6)
a95% confidence intervals.
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recruited men completed the study. Before unblind-
ing, two men were excluded from the efficacy analysis
for violation of the PSA inclusion criteria, but were
retained for the safety analysis.
In this small sample, group characteristics were not
equal at baseline on demographic variables. Age was
significantly lower in the active arm (69 years in active
group; 75 in placebo), while education was higher for
the active group. Significantly more men in the
placebo arm had been treated with radiotherapy-only
(Table I).
Mean PSA at baseline was 5.95 (range 0.43–28) for
the active treatment arm and 8.39 (range 2.4–22) for
the placebo group. The mean Gleason score was 7.1 in
the active arm, and 7.5 in the placebo group (range
6–9 for both groups).
Compliance
Adherence to protocol was excellent, ranging from
92% to 100%, except for one patient on placebo (78%).
Mean compliance in the active arm was 98.6% (SD
2.35, range 93–100), and in the placebo arm was 96.1
(SD 7.1, range 78–100). Throughout the treatment
phase, men maintained baseline dietary intakes of
trial foods, according to diet diaries.
Blinding
Evidence of blinding was obtained by eliciting
participants’ assessments of their group allocation at
the end of treatment prior to code breaking. Of those
in the active group who made an assessment, 50%
were correct, while 60% of those on placebo guessed
correctly.
Adverse Events
Overall, the intervention and control tablets were
well tolerated. There were 12 reported adverse events
(AEs) in the active treatment arm, three of which were
probably study-related (Table II), and one possibly
TABLE IV. PSA Doubling Times and Slopes: Individual Data
ID
no. Age
Gleason
score,
pre-op
Tumour
stage
Testosterone
baseline
PSA
baseline
PSA
end
PSA-DT
baseline
PSA-DT
end
PSA log
slope
baseline
PSA log
slope
end
Placebo group
1 84 7 (4 þ 3) 1c 10.50 12.42 12.18 12.38 402.99 0.056 0.002
2 77 7 (4 þ 3) 3a 14.60 3.10 2.76 13.69 11.19 0.051 0.062
5 58 9 (4 þ 5) 3b 23.60 14.50 23.50 8.69 8.75 0.080 0.079
9 63 9 (4 þ 5) 2c 9.10 2.40 3.90 10.93 7.22 0.063 0.096
10 69 9 (4 þ 5) 2c 9.40 3.50 4.40 15.11 310.83 0.046 0.002
12 81 7 (4 þ 3) 2a 13.70 7.50 9.10 13.24 infinite 0.052 -0.006
14 79 7 (3 þ 4) 3a 29.80 9.30 10.60 12.57 1612.0 0.055 0.000
16 78 7 (4 þ 3) 2c 10.50 9.12 14.65 7.25 3.63 0.096 0.191
17 76 8 (4 þ 4) 3a 13.10 4.60 6.40 8.23 3.81 0.084 0.182
20 83 7 (4 þ 3) 2c 13.20 22.00 21.70 10.49 34.12 0.066 0.020
21 76 6 (3 þ 3) 1c 14.70 3.90 5.10 11.53 9.82 0.060 0.071
Mean 75 7.5 14.75 8.39 10.39 10.75 10.90 0.064 0.064
(SD) (8.3) (6.39) (6.02) (7.09) (0.008) (0.035)
Active treatment group
3 56 8 (4 þ 4) 2c 9.10 0.85 1.43 9.16 3.13 0.076 0.222
4 69 7 (4 þ 3) 3b 17.00 5.20 6.60 9.84 6.49 0.070 0.107
7 70 8 (3 þ 5) 3a 19.40 0.60 1.20 10.16 3.86 0.068 0.179
8 77 6 (4 þ 3) 3a 7.20 5.40 14.90 5.41 2.00 0.128 0.347
11 65 9 (4 þ 5) 3a 8.50 0.43 0.49 21.20 12.69 0.033 0.055
13 66 7 (3 þ 4) 3b 22.00 0.46 0.49 21.67 13.89 0.032 0.050
15 65 6 (3 þ 3) 1c 26.60 4.20 5.60 13.20 34.66 0.053 0.020
19 74 7 (3 þ 4) 1c 15.10 28.00 38.00 7.77 6.52 0.089 0.106
22 71 6 (3 þ 3) 3a 15.40 8.40 9.00 11.06 12.90 0.063 0.054
Mean 69 7.1 15.59 5.95 8.63 10.20 5.48 0.068 0.127
(SD) (6.4) (6.54) (8.74) (12.02) (0.009) (0.038)
Calculated using linear mixed model.
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related (headache). Of these three, one case of heart-
burn and one of restlessness (probably caffeine-
related) persisted throughout the treatment phase.
Two men experienced increased nocturia initially, but
this symptom resolved after 1 and 2 weeks, respec-
tively. All were mild, except for the heartburn, which
was rated as moderate. There were 13 AEs in the
placebo arm, three of which were possibly related to
the green oats in the capsules, namely bloating (one
case), flatulence [1], and constipation [2].
Monitoring of dietary caffeine through a dairy
revealed no increase in participants’ dietary caffeine
intake across the treatment phase that could have
exacerbated any of these adverse events.
Effect on PSA Doubling Time
The results of the PSA kinetics are shown in
Tables III and IV and Figure 1. The doubling times
from randomization to 12 weeks are not statistically
significantly different between the two groups
(P¼ 0.22). The change in slope at the time of
randomization is not statistically significantly differ-
ent between the two groups (P¼ 0.21). The change
in slope of log PSA at the time of randomization
was not significant for either group (P¼ 0.98 for the
placebo group and P¼ 0.09 for the herbal treatment
group).
Effect on Secondary Outcome Measures
The results of effects on prostate symptoms as
measured on the IPSS, and anxiety and depression
measured on the HADS are shown in Table V.
A non-significant reduction in anxiety was ob-
served in the placebo group, consistent with known
activity of green oats, the placebo ingredient for the
broccoli powder capsules.
There was a non-significant reduction in depres-
sion scores in the active treatment arm, and a non-
significant reduction in IPSS scores in placebo group.
Results regarding the impact on health-related
quality of life and prostate-related symptoms measured
on the EORTC QLQ-C30 v3 and EORTC PR-25
respectively are presented in Tables VI and VII. Data
for the individual symptom clusters (fatigue, nausea,
and vomiting, dyspnea, pain, insomnia, appetite loss,
constipation, diarrhea, financial difficulties) are not
included, but there were no significant changes across
time for either group on any of these variables.
DISCUSSION
The goal of the current study was to assess, in a
small number of participants, the feasibility of a
randomized study on the phytotherapeutic combina-
tion of turmeric, resveratrol, green tea and broccoli
sprouts in men with BCR. Feasibility was demon-
strated in that processes to package and deliver the
experimental compounds along with matching
placebo tablets were logistically manageable, the
phytotherapeutic combination well-tolerated, and
adherence to protocol was high despite the number of
tablets and capsules administered (four of each daily),
with mild side effects reported. The burden of
completing outcome measurements was also accepted
with high compliance.
Limitations
The main limitation was the slow rate of recruit-
ment and the resultant smaller numbers of partic-
ipants. This was partly due to the introduction
of PSMA (Prostate-Specific Membrane Antigen)
Fig. 1. PSA changes of individuals.
TABLE V. Effect of Intervention on Prostate Symptoms (IPSS) and Anxiety and Depression (HADS)
IPSS HADS depression HADS anxiety
Baseline End of treatment Baseline End of treatment Baseline End of treatment
Placebo, n¼ 11 11 (10.48) 8.55 (5.65) 2.82 (3.63) 2.91 (3.08) 3.91 (4.60) 2.91 (3.21)
Active, n¼ 9 7.67 (6.96) 8.55 (8.13) 3.0 (2.55) 2.22 (2.59) 2.33 (2.18) 3.0 (3.5)
Scores expressed as mean and standard deviation where higher scores reflect higher level of dysfunction.
IPSS, International Prostate Symptom Score; HADS, Hospital Anxiety and Depression Score.
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Positron-Emission Tomography scans at the
recruitment hospital, which meant that micro-
metastases were detected in many otherwise eligi-
ble men with BCR, who were then directed to
salvage treatments.
The study was not powered to detect effects on any
outcome measures including PSA kinetics. However,
randomization failed to allocate patients treated with
surgical and radiation therapy evenly to active and
placebo in this small sample. PSA tests were not
always undertaken at the same laboratory and hence,
some variation is to be expected as there can be over
20% difference in results with laboratories using
different assays [38]. Baseline PSA measurements
were collected at screening, and not repeated on the
date of randomization. The period between these two
points ranged from 9 days to 3 months in one case,
due to the time taken to collect blood assays and
dispense tablets. Most end-of-treatment PSA measure-
ments were obtained within a week of trial comple-
tion, but a delay of 37 days (1.2 months) was
experienced in one participant. PSA kinetics also
improved in several men in the placebo arm during
the treatment phase. This is unlikely to be related to
the activity of green oats (Avena sativa), chosen as the
placebo for the broccoli capsules, which has no
demonstrated activity in prostate cancer [35,36].
This feasibility study was undertaken with no
specific funding so additional end-of-treatment blood
assays were not performed. However, all four compo-
nents of the study intervention have previously been
widely used and tested in humans and hence, phar-
macokinetic data was not sought in this study [39].
Recommendations
This pilot study of a phytotherapeutic intervention,
composed of turmeric, resveratrol, green tea and
broccoli sprouts, was of interest to men with BCR
prostate cancer and their treating oncologists. The
tablet formulation and dosages were acceptable to the
men and adverse events were few and mild. While
the data on PSA trends did suggest worse outcomes
for PSA in the herbal group, the differences were not
significant, and the width of the confidence intervals
in Table III allows the possibility that in a future
study, those on the herbal group would have a better
PSA outcome, consistent with other recent promising
trials of similar herbal interventions [33,34].
The introduction of PSMA scans has resulted in
earlier detection of micrometastases. Issues of trial
eligibility will need to be carefully considered in future
studies. Recruitment of sufficient numbers for a fully
powered study would necessitate a larger number of
trial sites. Stratification for initial therapy method could
be considered to ensure similar numbers of post-
surgical and post-radiotherapy patients are assigned to
each arm, while PSA data should be collected on the
date of randomization in future studies. It would also
be useful collect end-of-treatment testosterone in addi-
tion to the baseline assays in future studies.
CONCLUSIONS
The findings of this pilot study suggest that a fully-
powered study of this combination is feasible in men
with biochemically recurrent prostate cancer and a
moderate PSA rise rate.
The formulation was of high quality, manufactured
under pharmaceutical Good Manufacturing Practices
(GMP) in Australia, and contained therapeutically
active levels of constituents. The dose and percentage
of active constituents were determined in conjunction
with a phytochemist with over 30 years’ experience
(KB) to ensure therapeutic doses were achieved.
The success of blinding of participants was demon-
strated by comparing patients’ group allocation with
their assessment of group assignation elicited prior to
code-breaking.
The inclusion of a placebo arm overcame any
false positive results due to the natural variability
of PSA-DT [40].
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